Key result
Cardiomyocyte-specific overexpression of ATRAP completely suppressed the development of cardiac hypertrophy provoked by chronic angiotensin II infusion in mice.
Why the study?
Does cardiomyocyte-specific overexpression of ATRAP prevent cardiac hypertrophy in chronic angiotensin II-infused mice?
Does cardiomyocyte-specific overexpression of ATRAP prevent cardiac hypertrophy in chronic angiotensin II-infused mice?
Cardiomyocyte-specific overexpression of ATRAP abolishes cardiac hypertrophy provoked by chronic angiotensin II infusion in mice, identifying ATRAP as a potential novel therapeutic target.
No takes yet. Share an insight, caveat, or question.
No immediate clinical implications; leaves open ATRAP as a therapeutic target pending human studies.
Wakui et al. (2010) studied Cardiac hypertrophy. Cardiomyocyte-specific overexpression of ATRAP vs. Littermate control mice was evaluated on Development of cardiac hypertrophy. Cardiomyocyte-specific overexpression of ATRAP completely suppressed the development of cardiac hypertrophy provoked by chronic angiotensin II infusion in mice.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: